Max Robotics — Global Service Robot Directory + US Certification

About

Borivoj Golijanin is a urologic surgeon and researcher whose work spans the surgical management of urologic cancers, perioperative outcomes, and innovative drug delivery systems. His major contributions include investigating the "BMI Paradox" in robotic assisted partial nephrectomy, where he found that obese patients may experience comparable or better outcomes than non-obese patients—a counterintuitive finding with significant clinical implications. He has also advanced venous thromboembolism prophylaxis following robot-assisted radical cystectomy, demonstrating the feasibility of direct oral anticoagulants in this high-risk population. In the realm of translational oncology, Golijanin has pioneered the use of pH Low Insertion Peptides (pHLIPs) to target bladder urothelial carcinoma, showing that pHLIP-ICG can deliver cytotoxic agents like amanitin to inhibit cancer cell proliferation. His work on robotic prostatectomy outcomes, using national quality improvement data, identifies key risk factors for postoperative complications, informing safer surgical practices. With papers accumulating citations in the single to low double digits, Golijanin’s research is steadily gaining recognition for its practical impact on surgical oncology and targeted therapy.